Payment overview · 2025
General Payments
$9,381.07
204 reported records · 39 companies
Healthcare provider profile · identity verified
Manish B Viradia, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ANNANDALE, NJ · NPI 1457345324
Verified facts
What the public records show
CMS Open Payments records show Manish B Viradia, MD received $9,381.07 in general payments during 2025 across 204 reported records.
ARGENX US, INC. accounted for 68.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Botox, Ingrezza, Nourianz, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Rytary by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fycompa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
KYOWA KIRIN, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NOURIANZ as an associated drug or biological on 307 records involving 305 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nourianz by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Austedo Xr by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $6,390.58 | 68.1% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $590.38 | 6.3% | 41 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $301.80 | 3.2% | 27 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $257.68 | 2.8% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $237.40 | 2.5% | 11 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $213.80 | 2.3% | 19 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $210.67 | 2.2% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $120.66 | 1.3% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $85.77 | 0.9% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $83.20 | 0.9% | 4 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $71.48 | 0.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.78 | 0.7% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.90 | 0.6% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $51.03 | 0.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.11 | 0.5% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $47.45 | 0.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $45.85 | 0.5% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $36.74 | 0.4% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.18 | 0.4% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $33.42 | 0.4% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $33.40 | 0.4% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$33.13 | 0.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.00 | 0.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.48 | 0.3% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $23.83 | 0.2% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $23.81 | 0.2% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $22.04 | 0.2% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $20.66 | 0.2% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.96 | 0.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $19.72 | 0.2% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $19.02 | 0.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.21 | 0.2% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $17.55 | 0.2% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$15.37 | 0.2% | 1 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.12 | 0.2% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $14.78 | 0.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $13.94 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 0.1% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.54 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $4,500.00 | 1 |
| Food and Beverage | $3,256.71 | 195 |
| Travel and Lodging | $1,624.36 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $6,390.58 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $550.11 | 38 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $350.39 | 32 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $257.68 | 10 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $210.67 | 12 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $194.41 | 9 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $180.74 | 9 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $161.08 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $155.50 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.55 | 16 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $129.62 | 9 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $120.66 | 7 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $112.62 | 10 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $106.10 | 7 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $101.18 | 9 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $85.77 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $83.20 | 4 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $71.48 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $53.90 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $51.03 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $49.41 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $48.35 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $45.85 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $36.74 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $35.18 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $33.42 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $33.40 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| AGAMREE Normalized: agamree |
Drug | CATALYST PHARMACEUTICALS, INC. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $7.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BOTOX botox |
2025 | Botox | 2024 | 26 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NOURIANZ nourianz |
2025 | Nourianz | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
107 | 26 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| KYOWA KIRIN, INC. Exact reporting entity; no affiliate inference |
2025 | NOURIANZ open payments reported associated product |
CMS Open Payments — General Payments 307 supporting records · 305 recipient NPIs · example record 1222071383 |
Nourianz · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 611 | 176 |
| Pregabalin | Pregabalin | 324 | 63 |
| Alprazolam | Alprazolam | 297 | 67 |
| Diazepam | Diazepam | 249 | 47 |
| Memantine Hcl | Memantine Hcl | 244 | 71 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 196 | 34 |
| Primidone | Primidone | 183 | 44 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 172 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 151 | 46 |
| Topiramate | Topiramate | 143 | 34 |
| Baclofen | Baclofen | 126 | 33 |
| Sumatriptan Succinate | Sumatriptan Succinate | 109 | 18 |
| Clonazepam | Clonazepam | 107 | 21 |
| Rytary | Carbidopa/Levodopa | 107 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 30 |
| Donepezil Hcl | Donepezil Hcl | 104 | 29 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 96 | suppressed |
| Lorazepam | Lorazepam | 95 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 23 |
| Levetiracetam Er | Levetiracetam | 80 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 18 |
| Ubrelvy | Ubrogepant | 64 | 12 |
| Lacosamide | Lacosamide | 62 | 12 |
| Levetiracetam | Levetiracetam | 60 | 20 |
| Ondansetron Odt | Ondansetron | 58 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 55 | 16 |
| Methylphenidate Hcl | Methylphenidate Hcl | 54 | suppressed |
| Qulipta | Atogepant | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 21 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 50 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 50 | 11 |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 50 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 50 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Carbamazepine Er | Carbamazepine | 46 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 46 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | 15 |
| Tramadol Hcl | Tramadol Hcl | 44 | 16 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 41 | suppressed |
| Prednisone | Prednisone | 41 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Topamax | Topiramate | 39 | suppressed |
| Austedo Xr | Deutetrabenazine | 37 | suppressed |
| Carisoprodol | Carisoprodol | 35 | suppressed |
| Austedo | Deutetrabenazine | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 11 |
| Lamotrigine Er | Lamotrigine | 27 | suppressed |
| Modafinil | Modafinil | 27 | suppressed |
| Nayzilam | Midazolam | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Botox | Onabotulinumtoxina | 26 | 11 |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 26 | suppressed |
| Lamictal | Lamotrigine | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Buprenorphine | Buprenorphine | 25 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 25 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 24 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 24 | suppressed |
| Carbatrol | Carbamazepine | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Lamictal Xr | Lamotrigine | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Nourianz | Istradefylline | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 17 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Keppra Xr | Levetiracetam | 16 | suppressed |
| Topiramate Er | Topiramate | 16 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Armodafinil | Armodafinil | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 14 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 14 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Fycompa | Perampanel | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Risperdal | Risperidone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,381.07 · 204 records | ARGENX US, INC. | AGAMREE, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, DAXXIFY, EPIDIOLEX, Exablate, Gamunex-C, General - DBS, Hizentra, INGREZZA, INSPIRE, KISUNLA, Leqembi, Motpoly XR, NOURIANZ, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONGENTYS, ONPATTRO, Ocrevus Zunovo, PANZYGA, PEMGARDA, PONVORY, PRECIVITYAD2, QULIPTA, SKYCLARYS, SYMPAZAN, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, ZAVZPRET, ZEPOSIA | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error